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of current antipsychotic medication is cost-effective despite higher costs of antipsy-
chotic medication. Positive clinical and economic results persisted over 24 months.
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OBJECTIVES: To assess the cost-effectiveness of memantine in moderate and severe 
AD patients who exhibit agitation/aggression and psychotic symptoms (APS) from the 
UK National Health Service and Personal Social Services perspective. METHODS: 
The cost-utility analysis was based on 5-year Markov cohort simulations. The model 
evaluated the impact of memantine on time to Full-Time-Care (FTC), Quality-
Adjusted-Life-Years (QALYs) and costs, in pre-FTC patients compared with standard 
care, i.e. no pharmacotherapy or background treatment with acetylcholinesterase 
inhibitors. FTC was deﬁ ned based on locus of care and patient’s physical and func-
tional dependency status. Transition probabilities, baseline characteristics, resource 
utilization volumes, health utility weights and mortality rates were derived from the 
4.5-year London and South-East Region (LASER-AD) epidemiological study. Effec-
tiveness estimates came from a meta-analysis of six large randomised clinical trials. 
Costs covered routine patient management, hospitalization, social community services, 
institutionalization, and medications. Results were reported in EUR (GBP), 2009. The 
model underwent extensive stochastic and one-way sensitivity analyses, testing the 
model assumptions and changes in input parameters. RESULTS: Over ﬁ ve years, 
patients receiving standard care spend on average 78.8 weeks in the pre-FTC state. 
Overall costs in this group were c117,960 (£98,810). QALYs were estimated at 1.49 
(30% of full health). Memantine was associated with a longer time-to-FTC of 11.2 
weeks, QALY gains of 0.07 and cost-savings of c5930 (£4970). Lower costs in the 
memantine group were due to prolonged pre-FTC period. Memantine was more effec-
tive and less costly strategy relative to standard care in 99.98% of simulations. The 
estimated beneﬁ ts and cost savings were almost twice higher than those previously 
estimated in all moderate and severe AD patients, largely due to enhanced efﬁ cacy of 
memantine in APS patients, who, when left untreated, rapidly deteriorate. CONCLU-
SIONS: The model showed that memantine yielded higher beneﬁ ts at no additional 
costs relative to its alternative.
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OBJECTIVES: This analysis investigates the relative efﬁ ciency in the treatment of BD 
with the use atypical antipsychotics (AA): aripiprazole (ARI); olanzapine (OLA); 
quetiapine (QUE); risperidone (RIS); and ziprasidone (ZIP). METHODS: our analysis 
takes into consideration the treatment cost of AA and the impact on hospitalization 
costs associated with each AA. Mean daily dose of each AA, length of treatment and 
the probability of hospitalization for each AA were obtained from a retrospective 
study (90 days of follow-up) in 6,162 BD patients (Jing et al. 2009). The minimum 
acquisition cost per mg. of the mean daily dose, for each AA, is regarded as an efﬁ -
ciency criterion in Hospital Pharmacy Departments. The cost per day of hospitaliza-
tion (c347.90) and the length of hospitalization associated to BD (18.1 days; 
14.5–21.7) were obtained from a Spanish study. RESULTS: after 90 days of follow-up, 
hospitalization rates were higher with OLA (8.7%), QUE (8.5%), RIS (8.6%) and 
ZIP (10.2%) in comparison with ARI (5.9%; 5.8%; 5.7%; 6.5%, respectively). The 
treatment of BD with ARI gave rise to the following cost savings per patient, in relation 
to other AA: c149.31 ARI versus OLA; c33.42 ARI versus QUE; c19.45 ARI versus 
RIS; and c242.22 ARI versus ZIP. a sensitivity analysis tested the following variables: 
minimum daily dose for each AA; maximum daily dose for each AA; length of treat-
ment with AA; and probability of hospitalization for each AA. The sensitivity analysis 
conﬁ rms the cost savings associated with aripiprazole, with the only exception of 
risperidone where the cost saving per patient is almost neutral (c−2.89). CONCLU-
SIONS: using the criterion of cost rationalization based upon the minimum acquisition 
cost per mg. aripiprazole may have economic beneﬁ ts over other AA in terms of lower 
psychiatric treatment costs and lower total health care costs in the Spanish NHS.
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OBJECTIVES: To assess the efﬁ ciency of the drugs used to reduce relapses in schizo-
phrenia, taking into account costs and effectiveness (measured as QALY). METHODS: 
The National Health Care System perspective and a 1 year temporal horizon have 
been used. Taking into account the last NICE review on schizophrenia1, four funda-
mental aspects related with schizophrenia management were analyzed: relapse rates, 
treatment discontinuation due to intolerable side effects, treatment discontinuation 
due to other reasons and stable patients (where the probability of remission, EPS 
syndrome, weight gain, glucose intolerance and diabetes were analyzed). The health 
care direct costs corresponding to the drug acquisition costs have been analyzed 
together with the costs of the side effects considered, the cost of the complications 
(diabetes) and the costs of hospitalary relapses (stay and drug cost) updated with data 
from Spanish Ministry of Health (2008). a Monte Carlo simulation was performed 
to obtain the cost-effectiveness ratio (euros/QALY). RESULTS: Paliperidone ER pres-
ents the lower total costs (c3060) compared to the other strategies (risperidone = 
c3206; haloperidol = c3220; olanzapine = c3903; amisulpride = c4281; aripiprazole 
= c4719). Paliperidone ER presents the higher efﬁ cacy (QALY) compared to the other 
strategies (Paliperidone ER = 0.7573; risperidone = 0.7335; haloperidol = c0.7230; 
olanzapine = c0.7474; amisulpride = c0.7320; aripiprazole = c0.7379). With these 
results, we can conclude that all the strategies are dominated by Paliperidone ER with 
a C/E ratio of 4073 (risperidone = 4382; haloperidol = 4461; olanzapine = 5.235; 
amisulpride = 5.827; aripiprazole = 6.421) CONCLUSIONS: At a willingness-to-pay 
of c30,000 per QALY all the drugs considered are cost-effective in Spain. However, 
the most efﬁ cient (more net beneﬁ c, monetary (euros) and in health—QALYs) vs. 
Haloperidol are: paliperidone ER, followed by risperidone, olanzapine, amisulpride 
and aripiprazole.
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OBJECTIVES: To evaluate the cost-effectiveness of eight ﬁ rst line antipsychotics in 
the prevention of schizophrenia relapse, from a UK National Health Service and 
Personal Social Services perspective. METHODS: A Markov model, similar to that 
used by the National Institute for Health and Clinical Excellence in the Schizophrenia 
(update) guideline (published March 2009), was developed to assess the cost per 
QALY gained for amisulpride, aripiprazole, haloperidol, olanzapine, paliperidone, 
quetiapine (XL), risperidone and zotepine. Clinical parameters were populated with 
data from mixed treatment comparisons. Patients entered the model in remission and 
could remain in remission, relapse, move to next line of therapy due to side effects, 
or discontinue for other reasons. Utilities for schizophrenia in remission and relapse 
were taken from a direct utility elicitation study conducted in a UK population. Disu-
tilities for side effects were captured. Resource use and unit costs (reference year 2009) 
were taken from published sources and a 10 year time horizon was adopted. Proba-
bilistic results were derived from 10,000 model simulations. RESULTS: The determin-
istic analysis showed quetiapine (XL) to yield the most QALYs and lowest overall 
treatment costs. Model outcomes were supported by the probabilistic analysis but 
results were characterised by uncertainty. In one scenario, drug costs for all compara-
tors bar quetiapine (XL) were set to zero. Quetiapine (XL) generated 7.051 QALYs 
compared to a range of 6.930–6.972 for other medications. Overall treatment costs 
for quetiapine (XL) were £153,104 compared to £155,766-£167,329 for other medi-
cations. Thus it was still the dominant strategy. CONCLUSIONS: The additional 
beneﬁ t of Quetiapine (XL) in terms of schizophrenia relapse prevention results in it 
being the most cost-effective of the antipsychotics assessed. Clinical efﬁ cacy is the key 
driver of cost-effectiveness in relapse prevention, hence generic antipsychotics should 
not be recommended based upon drug costs alone. Further long term trials of anti-
psychotics are required to reduce uncertainty.
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OBJECTIVES: a cost-utility analysis of agomelatine, a treatment of major depressive 
disorders in adults, was performed from the Polish public payer’s perspective (the 
National Health Fund). Agomalatine was compared with the most commonly used 
antidepressants in Poland, i.e. generic sertraline and generic venlafaxine. METHODS: 
The analysis with a time horizon of 2 years is based on a Markov model. The one-
month cycle model included the following health states: depression episode, remission, 
well and death. It also incorporated sleep disorders, discontinuation rates, discontinu-
ation symptoms and adverse drug reactions. The clinical parameters for compared 
drugs were extracted from head-to-head clinical trials. Utility and disutility estimates 
were derived from a systematic literature review. Only direct costs have been consid-
ered in order to be consistent with Polish pharmacoeconomic guidelines. Costs and 
effects were discounted at 5% and 3.5% per annum at year 1 respectively. RESULTS: 
The beneﬁ t of agomelatine over sertraline or venlafaxine was estimated at 0.005 
QALY. This effectiveness was associated with the additional costs of 491 PLN and 
149 PLN for agomelatine compared to sertraline and venlafaxine, respectively. The 
corresponding agomelatine incremental cost-utility ratios (ICURs) were therefore 
92,000 PLN/QALY and 28,000 PLN/QALY. Sensitivity analysis demonstrated that 
agomelatine ICUR remained below the three times GDP per capita threshold (33,347 
PLN for 2008) in 79.7% and 88.4% of the cases compared with sertraline and ven-
lafaxine, respectively. CONCLUSIONS: From the Polish public payer’s perspective, 
